NSCLC
Conditions
Interventions
None listed
Sponsors
Shonan Fujisawa Tokushukai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients were consecutively enrolled from the TREAD-01 database. To be eligible for enrollment, patients had to be at least 20 years of age at the start of treatment, and have cytologically or pathologically confirmed non-small cell lung cancer with sensitizing EGFR mutations (Del19 or L858R), including those with compound EGFR mutations. Patients were categorized as having untreated stage III disease for which curative therapy was not feasible, stage IV disease (according to the 8th edition of the American Joint Committee on Cancer staging criteria for lung cancer), or recurrent disease after curative treatment. All patients were receiving first-line treatment with gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib between April 2010 and 2022 at the 47 hospitals participating in the TREAD project.
Exclusion criteria
Exclusion criteria: Exclusion criteria for this study include: de novo EGFR T790M mutation, opt-outs who refused to give informed consent, insufficient data extraction such as missing details of previous cancer treatment at other hospitals or individual patient data, simultaneous or metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, or disease-free for 5 years or less.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS | — |
Countries
Japan
Contacts
Public ContactMakoto Hibino
Shonan Fujisawa Tokushukai Hospital Resoiratory medicne
Outcome results
None listed